DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for scleroderma patients as experimental drug enters mid-stage trial
Disease control Recruiting nowThis study tests whether the experimental drug MTX-474 can safely reduce skin thickening in people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes hard, tight skin and can damage internal organs. About 85 adults with early-stage disease will recei…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated May 26, 2026 09:51 UTC
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage study tests a one-time treatment made from donor immune cells that are gene-edited to target and destroy faulty immune cells causing disease. It is for 80 adults with severe lupus, scleroderma, or myositis that have not responded to standard therapies. The main g…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated May 26, 2026 09:49 UTC
-
New drug trial aims to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new medicine, SAR448501/DR-0201, in adults with lupus or rheumatoid arthritis. The goal is to find safe and tolerable doses by checking side effects and how the drug works in the body. About 62 participants will receive multiple doses and be followe…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated May 26, 2026 09:49 UTC
-
Promising new drug targets skin and lung damage in scleroderma
Disease control Recruiting nowThis study tests a new drug called ianalumab in 200 adults with a severe form of scleroderma that affects the skin and internal organs. The goal is to see if it can improve skin hardening and lung function compared to a placebo over 52 weeks. Participants must be between 18 and 7…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-phase trial tests an experimental treatment called QEL-005 in 16 adults with two autoimmune diseases: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically modifie…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated May 26, 2026 08:19 UTC